<DOC>
	<DOCNO>NCT01671774</DOCNO>
	<brief_summary>The purpose trial assess immunological effect kinetics , safety activity IMAB362 plus Zoledronic acid with/without low intermediate dos Interleukin-2 subject advanced gastroesophageal cancer .</brief_summary>
	<brief_title>Safety Activity IMAB362 Combination With Zoledronic Acid Interleukin-2 CLDN18.2-positive Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically confirm adenocarcinoma stomach , esophagus gastroesophageal junction Inoperable locally advance disease , resection R0 , R1 R2 outcome metastatic disease . CLDN18.2 expression confirm immunohistochemistry paraffin embed tumor tissue sample . Measurable and/or nonmeasurable disease define accord RECIST v1.1 Age â‰¥ 18 year Written inform consent ECOG performance status ( PS ) 01 Life expectancy &gt; 3 month Prior hypersensitivity reaction intolerance one compound study treatment Known HIV infection know symptomatic hepatitis ( A , B , C ) Clinical symptom cerebral metastasis Pregnancy breastfeed Patients treat bisphosphonatebased therapeutic indication previous year Hypocalcemia require medication . Corrected ( adjust serum albumin ) serum calcium &lt; 8 mg/dl ( 2 mmol/L ) &gt; 12 mg/dL ( 3.0 mmol/L )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>